By vgreene, 16 June, 2020 Effect of Regular Intravenous Immunoglobulin Therapy on Prognosis of Severe Pneumonia in Patients With COVID-19; access J Infect article
By vgreene, 16 June, 2020 Pilot Prospective Open, Single-arm Multicentre Study on Off-label Use of Tocilizumab in Patients With Severe COVID-19
By vgreene, 16 June, 2020 Study considerations: single-arm, open-label study; small sample size; heterogeneous antiviral tx and TCZ admin routes; SC dose based on PK in RA pts; timing of tx; limited f/u
By vgreene, 16 June, 2020 Overall mortality 11% (no difference btwn routes); oxygenation and D-dimer and CRP levels significantly improved over time; TCZ w/in 6 days from admission assoc w/ incr likelihood of survival (HR 2.2, 95% CI 1.3-6.7); no severe ADRs reported
By vgreene, 16 June, 2020 Prospective, open-label, single-arm, multicenter study; 63 hospitalized pts (mean age 62.6 y) w/ confirmed severe COVID-19 and markedly abnormal pro-inflammatory profile received TCZ 8 mg/kg IV (n=34) or 324 mg SC (n=29) x1 dose, 83% received 2nd dose w/
By vgreene, 15 June, 2020 Famotidine Use and Quantitative Symptom Tracking for COVID-19 in Hon-hospitalized Patients: A Case Series: full-text Gut article
By vgreene, 15 June, 2020 Famotidine Use is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study; full-text Gastroenterology article